In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

Theratechnologies’ supply hiccup is the second caused by third-party manufacturing problems in less than a week. On Friday, ...

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential ...

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...

Just a few months after the reveal of Ori Biotech’s automated cell and gene therapy manufacturing platform IRO, the technical ...

No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | ...

An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...

The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between ...

Equipped with a $200 million investment led by Bain’s Life Science arm, Serán has set its sights on the build-out of its ...

Three months after a jury awarded $260 million to an Oregon woman who claimed her use of Johnson’s Baby Powder caused her to ...

New biologics such as GSK's Benlysta and AstraZeneca's Saphnelo, along with off-label drugs, have been the mainstay for ...

Nearly a year after Coherus BioSciences’ on-body injector for Udenyca was rejected over external production issues, a ...